AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01307449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX
Description: 1 dose of PNEUMOVAX
Study NCT04525846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: * program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)
Study NCT04525846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non PFMT
Description: Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
Study NCT00732381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
Study NCT00732381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study NCT03400969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol 17%
Description: Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
Study NCT03400969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aequasyal (OGT)
Description: Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
Study NCT03400969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Salient (new product)
Description: Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
Study NCT04507945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutritional Therapy, Metabolic Disorder, Regular
Description: According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
Study NCT02852681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 15 mg E4/3 mg DRSP
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
Study NCT03546634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
Study NCT03546634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
Study NCT01307449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 1 dose of Prevnar
Study NCT01585727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision
Study NCT01585727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision
Study NCT01585727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring
Description: Intraoperative neuromonitoring of pelvic autonomic nerves.
Study NCT00579644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Minocycline and MTX or MTX alone
Description: Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg
Study NCT00579644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study.
Study NCT01688297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1 Oral Vaccine
Description: One or two doses of replication incompetent adenovirus oral tablet vaccine
Study NCT01688297 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablet
Description: Off-white tablets similarly formulated to the active drug product tablets.
Study NCT02694666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controlled whole-body vibration training
Description: The intervention is an 8-week program
Study NCT02694666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled whole-body vibration training
Description: The intervention is an 8-week program
Study NCT01597258 — intervention group
Intervention type: DRUG
Intervention: Crizotinib (Xalkori)
Description: XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status.
Study NCT03150238 — intervention group
Intervention type: OTHER
Intervention: observation of prognostic factors for relapse
Description: The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
Study NCT01779999 — intervention group
Intervention type: OTHER
Intervention: PICC-carrying patients
Description: Echographic monitoring of patients carrying a peripherally inserted central catheter
Study NCT04134143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: A round patch of experimental skin tissue that the doctor applies over the ulcer
Study NCT00573170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo
Study NCT03662308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Vest
Description: Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
Study NCT03662308 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Heated Vest
Description: Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
Study NCT03662308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Heated Vest
Description: A similarly insulated (compared to the experimental vest), but non-heated vest
Study NCT02529202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion
Study NCT04290286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i2TransHealth
Description: i2TransHealth: online intervention for TGD people
Study NCT02265341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02265341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT03119220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit One
Description: Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
Study NCT03227757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Repair System
Description: Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
Study NCT03047083 — intervention group
Intervention type: OTHER
Intervention: Treatment patterns among AML patients
Description: This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
Study NCT03047083 — intervention group
Intervention type: OTHER
Intervention: AML-related healthcare resources
Description: This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
Study NCT01801449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Study NCT02162446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satoreotide trizoxetan
Study NCT02339779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fat transfer
Description: Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast.
Study NCT02339779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast implant
Description: Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)
Study NCT02703714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given intravenously (IV)
Study NCT02703714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250 µg given subcutaneously (SC)
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of PEEP before and after CPB
Description: PEEP will be set in order to reach an airway pressure of 5 cmH2O
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No use of PEEP before and after CPB(ZEEP)
Description: No PEEP will be used
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No use of PEEP before and after CPB(ZEEP)
Description: No PEEP will be used
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with CPAP during CPB
Description: A continuous Positive Airway Pressure (CPAP) will be applied during CPB
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No ventilation during CPB
Description: No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
Study NCT02633423 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No ventilation during CPB
Description: No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
Study NCT04058990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Paclitaxel-Coated PTCA Balloon Catheter
Description: Percutaneous Transluminal Coronary Angioplasty
Study NCT04058990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
Description: Percutaneous Transluminal Coronary Angioplasty
Study NCT03071185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve block, common peroneal nerve block
Description: For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
Study NCT01013012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron with saline
Description: Group A : saline 1 ml, ramosetron 6μg/kg
Study NCT01013012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron with dexamethasone
Description: Group B : dexamethasone 4 mg, ramosetron 6μg/kg
Study NCT04057196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)
Description: The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
Study NCT03570957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: MT-2990 solution for injection in vial
Study NCT03570957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection in vial
Study NCT03570957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection in vial
Study NCT04358549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
Study NCT04358549 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care for individual study site as determined by each hospital's protocol
Study NCT03573999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 4.6 ml/kg will be administered before dura opening
Study NCT03573999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 7.5%
Description: 2 ml/kg will be administered before dura opening
Study NCT03297346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac imaging and circulating biomarkers
Description: Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
Study NCT02800434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand allograft
Study NCT03221569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: 0.3mg/kg IVPB over 15 minutes
Study NCT03221569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
Study NCT03221569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine.
Study NCT03221569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 1ml intravenous push as placebo for double-blinding purposes
Study NCT04632368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcendental Meditation
Description: TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
Study NCT03285685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
Study NCT03285685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
Study NCT03285685 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
Study NCT03988036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion; 200 mg; every 3 weeks
Study NCT03988036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Biosimilar ABP 980
Description: Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
Study NCT03988036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
Study NCT02086370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PBS
Description: the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
Study NCT02086370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical PBS
Description: the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
Study NCT01091233 — intervention group
Intervention type: PROCEDURE
Intervention: paracentesis
Description: as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
Study NCT00092014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate 35 mg
Description: Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental Calcium
Description: Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risendronate placebo
Description: Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT00092014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate placebo
Description: Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study NCT03903081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily